天疱疮缓解期抗Dsg抗体阳性患者的临床特征、预后及抗体致病性分析
该回顾性队列研究纳入132例曾达临床缓解的天疱疮患者,缓解时54.5%仍可检出抗Dsg抗体。阳性组与阴性组在减至5 mg/d泼尼松龙及复发率上无差异,但阳性组停用糖皮质激素者更少;体外实验显示缓解期全血清在7/9例中仍具致病活性。
要点
- 天疱疮临床缓解时约半数患者抗Dsg抗体仍阳性,不能仅凭抗体阳性判断疾病活动。
- 抗体阳性组停用糖皮质激素的比例显著低于阴性组,减药需更谨慎。
- 缓解期抗体仍可能保留致病活性,抗体滴度下降不等同于致病性消失。
核心结论
- 天疱疮患者达到临床缓解后抗Dsg抗体仍可在54.5%的患者中检出,但抗体阳性与减至5 mg/d泼尼松龙及复发率无关,仅与停用糖皮质激素比例较低相关。
- 缓解期全血清在7/9例中仍显示致病活性,且活动期与缓解期等量抗Dsg抗体的致病性相似。
研究设计与样本
- 回顾性队列研究,纳入2019至2020年就诊于庆应大学皮肤科、有临床缓解史的天疱疮患者。
- 缓解定义为PDAI=0且泼尼松龙≤10 mg/d持续2个月,共132例患者纳入分析。
- 抗体致病性通过珠聚集试验评估。
主要发现
- 132例缓解患者中72例(54.5%)抗Dsg抗体阳性(阳性组),60例(45.5%)阴性(阴性组)。
- 阳性组中33例有活动期数据者,缓解期抗Dsg抗体滴度较活动期下降。
- 阳性组与阴性组减至泼尼松龙5 mg/d的机会无差异(P=0.885),复发率无差异(P=0.279)。
- 阳性组停用糖皮质激素的患者少于阴性组(P=0.004)。
- 缓解期血清阻断Dsg/桥粒胶蛋白珠聚集的能力较活动期显著降低,但全血清在7/9例中仍有致病活性。
临床怎么用
- 天疱疮缓解期抗Dsg抗体阳性不应单独视为疾病活动或复发,需结合临床。
- 抗体阳性患者减停糖皮质激素时应更谨慎,尤其计划停药时。
- 抗体滴度下降不保证致病性消失,评估减药风险需综合考虑。
局限性
- 回顾性研究设计。
- 抗体致病性评估的病例数有限(全血清致病活性分析仅9例)。
- 单中心研究,样本来自特定时间段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The detection of serum anti-desmoglein (Dsg) IgG autoantibodies has been reported to be useful for assessment of disease activity in pemphigus. However, previous studies have reported that anti-Dsg autoantibodies remain detectable in some patients without active pemphigus lesions. OBJECTIVES: To investigate the clinical characteristics and antibody pathogenicity of pemphigus patients positive for anti-Dsg IgG autoantibodies in remission. METHODS: We retrospectively investigated pemphigus patients with a history of clinical remission who visited the Department of Dermatology of Keio University during 2019 and 2020. The antibody pathogenicity was assessed by bead aggregation assay. RESULTS: When patients were recognized as having entered remission (PDAI = 0 and PSL ≦ 10 mg/day for 2 months), serum autoantibodies against Dsg were detected in 72 of 132 patients (54.5%, positive group; PG), but were not detected in 60 patients (45.5%, negative group; NG). Anti-Dsg antibody titres in remission declined from the active phase in 33 patients in the PG for whom data were available. There were no differences in the chance of reducing PSL to 5 mg/day (P = 0.885) and rate of relapse (P = 0.279) between PG and NG, but fewer patients in PG discontinued corticosteroids (P = 0.004). The ability of patients' sera to block aggregation of Dsg/desmocollin beads was significantly reduced in remission compared to the active phase. However, our results revealed that whole sera in remission still had pathogenic activity in seven of nine patients, and the approximately equal amounts of anti-Dsg antibodies in active phase and remission showed similar pathogenicity. CONCLUSIONS: This study will provide guidance in cases where autoantibodies are found to be positive in pemphigus patients during remission or steroid reduction.
引用
- Zhao WL, Ishii K, Egami S, et al. Analysis of clinical characteristics, prognosis and antibody pathogenicity of pemphigus patients positive for anti-desmoglein IgG autoantibodies in remission: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2021. PMID: 34704306. doi:10.1111/jdv.17770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。